A Study of MT027 in Patients with Pleural Malignant Tumors
Status:
RECRUITING
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy..
Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.
Phase:
PHASE1
Details
Lead Sponsor:
Suzhou Maximum Bio-tech Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences